Findeklee S, Lotz L, Heusinger K, Hoffmann I, Dittrich R, Beckmann M W
Gynecology and Obstetrics, Universitätsklinikum Erlangen, Erlangen.
Gynecologic Endocrinology and Reproductive Medicine, Universitätsklinikum Erlangen, Erlangen.
Geburtshilfe Frauenheilkd. 2015 Dec;75(12):1243-1249. doi: 10.1055/s-0035-1558184.
Protecting the fertility of patients with oncologic disease is becoming more and more important, as fulfilling the wish to have children is increasingly occurring at a later stage in life and long-term survival rates after cancer are continuing to improve. A number of fertility-preserving options exist. In addition to techniques which have been around for some time such as medical ovarian suppression, ovarian transposition, and organ-preserving surgery, there are other, more recent, innovative methods which have developed over the last few years such as cryopreservation of oocytes or ovarian tissue transplantation after completing cancer therapy. As every procedure has its specific advantages and disadvantages, informed patient consent is essential. The physician's aim must be to select the optimal procedure for each patient. The extent of patients' information about the options to preserve fertility in women with oncologic disease remains limited. One of the main reasons for this is that clinicians are not sure how to inform patients about existing procedures and methods. The aim of this review article is to provide help in clinical practice.
随着生育愿望越来越多地出现在生命后期,且癌症患者的长期生存率持续提高,保护肿瘤疾病患者的生育能力变得越来越重要。目前有多种生育力保存方法。除了一些已存在一段时间的技术,如药物性卵巢抑制、卵巢移位和保留器官的手术外,过去几年还出现了其他更新的创新方法,如卵母细胞冷冻保存或在完成癌症治疗后进行卵巢组织移植。由于每种方法都有其特定的优缺点,因此患者的知情同意至关重要。医生的目标必须是为每位患者选择最佳方法。肿瘤疾病女性患者对生育力保存方法的了解程度仍然有限。主要原因之一是临床医生不确定如何向患者介绍现有方法。这篇综述文章的目的是为临床实践提供帮助。